| Autor: |
Tripathi SC; Department of Biochemistry, All India Institute of Medical Sciences Nagpur, Nagpur 441108, MH, India., Vedpathak D; Department of Biochemistry, All India Institute of Medical Sciences Nagpur, Nagpur 441108, MH, India., Ostrin EJ; Department of General Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Cells [Cells] 2021 Dec 20; Vol. 10 (12). Date of Electronic Publication: 2021 Dec 20. |
| DOI: |
10.3390/cells10123587 |
| Abstrakt: |
Cell-mediated immunity is driven by antigenic peptide presentation on major histocompatibility complex (MHC) molecules. Specialized proteasome complexes called immunoproteasomes process viral, bacterial, and tumor antigens for presentation on MHC class I molecules, which can induce CD8 T cells to mount effective immune responses. Immunoproteasomes are distinguished by three subunits that alter the catalytic activity of the proteasome and are inducible by inflammatory stimuli such as interferon-γ (IFN-γ). This inducible activity places them in central roles in cancer, autoimmunity, and inflammation. While accelerated proteasomal degradation is an important tumorigenic mechanism deployed by several cancers, there is some ambiguity regarding the role of immunoproteasome induction in neoplastic transformation. Understanding the mechanistic and functional relevance of the immunoproteasome provides essential insights into developing targeted therapies, including overcoming resistance to standard proteasome inhibition and immunomodulation of the tumor microenvironment. In this review, we discuss the roles of the immunoproteasome in different cancers. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
